Sexual Dimorphism in Doxorubicin-induced Systemic Inflammation: Implications for Hepatic Cytochrome P450 Regulation
Open Access
- 14 February 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (4), 1279
- https://doi.org/10.3390/ijms21041279
Abstract
Doxorubicin (DOX) is an effective chemotherapeutic agent used to treat a wide variety of malignancies. In addition to its multi-organ toxicity, DOX treatment has been shown to induce systemic inflammation in patients and experimental animals. Inflammation alters the expression of hepatic cytochrome P450 (CYP) enzymes, which play important roles in drug metabolism and DOX-induced toxicity. Significant sex differences have been reported in DOX-induced toxicity; however, sex differences in DOX-induced systemic inflammation and the potential effects on hepatic CYP expression have not been determined. In the current work, male and female C57Bl/6 mice were administered DOX (20 mg/kg by intraperitoneal injection), and groups of mice were sacrificed 24 and 72 h after DOX administration. DOX elicited a systemic inflammatory response in both male and female mice, but the inflammatory response was stronger in male mice. DOX altered the expression of hepatic CYP isoforms in a sex-dependent manner. Most notably, inhibition of Cyp2c29 and Cyp2e1 was stronger in male than in female mice, which paralleled the sex differences in systemic inflammation. Therefore, sex differences in DOX-induced systemic inflammation may lead to sexually dimorphic drug interactions, in addition to contributing to the previously reported sexual dimorphism in specific DOX-induced organ toxicity.Funding Information
- Masonic Cancer Center, University of Minnesota (N/A)
- Rally Foundation (582420)
This publication has 43 references indexed in Scilit:
- Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasomeCancer Biology & Therapy, 2011
- Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heartCardiovascular Research, 2011
- Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammationPharmacological Research, 2010
- Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammationJournal of Molecular and Cellular Cardiology, 2010
- Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in ratsToxicology and Applied Pharmacology, 2010
- Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human HepatocytesDrug Metabolism and Disposition, 2007
- Differential alteration of drug metabolizing enzyme activities after cyclohosphamide/adriamycin administation in breast cancer patientsMethods and Findings in Experimental and Clinical Pharmacology, 2007
- Down‐regulation of aryl hydrocarbon receptor–regulated genes by tumor necrosis factor‐α and lipopolysaccharide in murine hepatoma hepa 1c1c7 cellsJournal of Pharmaceutical Sciences, 2005
- Astroglial CYP1B1 up-regulation in inflammatory/oxidative toxic conditions: IL-1β effect and protection by N-acetylcysteineToxicology Letters, 2003
- Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia ProtocolJournal of Clinical Oncology, 2002